Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss

Inclusion criteria

• Male subject aged 18-41 years old with skin type I to IV according to the Fitzpatrick scale;
• Affected by androgenetic alopecia with hair loss evaluated grade IIA to IV the modified Norwood-Hamilton scale;
• Subject with chestnut brown, dark or black hair;
• Subject with hair length ≥ 3 cm on the vertex and agreeing to keep this minimum length for the duration of the study;
• Subject agreeing to have a shaved zone of 1.5 cm² on scalp area;
• Subject accepting not to dye, bleach his hair or to do a permanent wave during the whole study duration;
• Subject accepting to use condoms if her partner is pregnant.

Exclusion criteria

• Female subject;
• Subject presenting a life-threatening endocrine disease, neoplasia or other serious diseases;
• Subjects suffering from chemo-induced alopecia (poisoning, medicines), or resulting from a chronic disease (genetic, endocrine, immunological, deficiencies), seasonal hair loss;
• Subject having any other concomitant dermatological affection of the scalp (psoriasis, seborrheic dermatitis, eczema, other alopecia than androgenetic);
• Subject suffering from a recurrent, acute, non-stabilized or evolving disease judged by the investigator able to interfere with the study needs and hair growth;
• Subject having had surgical intervention for capillary correction (e.g., hair transplant) or intending to have recourse to this surgery during the entire study period;
• Subject presenting a hypersensitivity to any of the components of the finasteride medication or to any 5-alpha-reductase inhibitor;
• Subject that has applied or taken prior to the start of the study (screening) interfering drugs or products
• Subject taking any other medical treatment (topic or per os) likely to interfere on hair growth or hair loss within 6 months prior to the screening visit;
• Subject following a long period (>30 days) treatment of anti-inflammatory within 4 months prior to the start of the study (screening visit);
• Subject taking topic cosmetic treatment or per os nutritional supplement likely to interfere on hair growth or hair loss during the last 3 months prior to the screening visit;
• Subject having a topical or oral route treatment of the scalp (anti-seborrheic, anti-dandruff, daily friction) within 2 weeks prior to the screening visit;
• Subject who has been exposed within one month prior to the screening visit in an intense or excessive manner to sun (natural or artificial) or during the study;
• Subject having a wig or hair extension;
• Protected subject as defined in the Articles of the French Public Health Code. Article 1121-7: person deprived of liberty by a judicial or administrative decision, or subject to psychiatric care, or person admitted to a health or social institution for purposes other than the research. Article 1121-8: adult person subject to a legal protection measure or unable to express his/her consent;
• Subject unable to communicate or cooperate with the Investigator due to poor mental development, language problems or impaired cerebral function;
• Subject currently participating in another clinical study or being in an exclusion period of another clinical study;